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This study aimed to ascertain gene expression profile differences between progressive muscle‑invasive 
bladder cancer (MIBC) and de novo MIBC, and to identify prognostic biomarkers to improve patients’ 
treatment. Retrospective multicenter study in which 212 MIBC patients who underwent radical 
cystectomy between 2000 and 2019 were included. Gene expression profiles were determined in 26 
samples using Illumina microarrays. The expression levels of 94 genes were studied by quantitative 
PCR in an independent set of 186 MIBC patients. In a median follow‑up of 16 months, 46.7% patients 
developed tumor progression after cystectomy. In our series, progressive MIBC patients show a 
worse tumor progression (p = 0.024) and cancer‑specific survival (CSS) (p = 0.049) than the de novo 
group. A total of 480 genes were found to be differently expressed between both groups. Differential 
expression of 24 out of the 94 selected genes was found in an independent cohort. RBPMC2 and DSC3 
were found as independent prognostic biomarkers of tumor progression and CALD1 and LCOR were 
identified as prognostic biomarkers of CSS between both groups. In conclusion, progressive and de 
novo MIBC patients show different clinical outcome and gene expression profiles. Gene expression 
patterns may contribute to predict high‑risk of progression to distant metastasis or CSS.
Abbreviations
AUA  American Urological Association
CSS  Cancer specific survival
Cq  Cycle quantification
DEGs  Differentially expressed genes
EAU  European Association of Urology
EMT  Epithelial-mesenchymal transition
FDR  False discovery rate
FFPE  Formalin-fixed paraffin-embedded
GSEA  Gene set enrichment analysis
KEGG  Kyoto Encyclopedia of Genes and Genomes
LN  Lymph nodes
MIBC  Muscle-invasive bladder cancer
NMIBC  Non-muscle-invasive bladder cancer
RC  Radical cystectomy
RT-qPCR  Reverse transcription quantitative PCR
TCGA  The Cancer Genome Atlas
TURBT  Transurethral resection of the bladder tumor
OPEN
1Laboratory and Department of Urology, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer 
(IDIBAPS), Universitat de Barcelona, Barcelona, Spain. 2Department of Urology, Radboud University Medical 
Center, Nijmegen, The Netherlands. 3CIBERehd, Plataforma de Bioinformática, Centro de Investigación Biomédica 
en red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain. 4Laboratory of Urology, Hospital Clínic de 
Barcelona, Centre de Recerca Biomèdica CELLEX, office B22, C/Casanova, 143, 08036 Barcelona, Spain. 5These 
authors contributed equally: Raquel Carrasco and Laura Izquierdo. *email: lmengual@clinic.cat
2
Vol:.(1234567890)
Scientific Reports |         (2021) 11:6132  | https://doi.org/10.1038/s41598-021-85137-1
www.nature.com/scientificreports/
At diagnosis, 75% is non-muscle-invasive bladder cancer (NMIBC) and 25% is muscle-invasive bladder cancer 
(MIBC) or  metastatic1. NMIBC and MIBC show differences in terms of prognosis and  treatment2. However, 
high-grade NMIBC invades deep into the lamina propria and share morphologic, clinical and molecular char-
acteristics with MIBC, including aggressive behavior and lethality  potential3,4. Therefore, despite proper NMIBC 
management, about 40–50% of high grade non-invasive tumors will progress to MIBC during follow-up5.
Both, progressive and de novo MIBC are treated with radical cystectomy (RC), but a different clinical outcome 
has been described between both MIBC groups after RC. Several studies have shown that progressive MIBC 
had a significantly worse prognosis compared to de novo invasive  tumors6,7, although it remains a controversial 
issue. Chen et al.8 did not find survival differences between progressive and de novo MIBC groups in a set of 
4102 patients. Contrarily, more recently, Peng Ge et al.9 demonstrated survival differences between both groups 
in a series of 4075 MIBC patients, where progressive MIBC patients had a worse cancer specific survival (CSS) 
than de novo group. These survival differences may indicate that progressive MIBC harbor genetic characteristics 
which confer them with a more aggressive conduct than de novo MIBC. Therefore, both MIBC groups could 
represent different molecular entities and biological behavior. In a recent study, Pietzak et al.10 demonstrated 
that progressive MIBC had lower response rates to neoadjuvant chemotherapy compared with de novo MIBC, 
also suggesting genetic differences between both MIBC groups.
Currently, there is no data regarding the molecular features of progressive and de novo MIBC and therefore, 
the risk of progression is determined according to clinicopathological parameters defined European Association 
of Urology (EAU) or American Urological Association (AUA) urology  guidelines11,12. However, these clinico-
pathological parameters are not accurate enough to stratify those patients that will develop tumor progression 
from those who will not, and patients with high-risk progression tumors may obtain an inappropriate  treatment9.
Here, we examine gene expression patterns of progressive and de novo MIBC to elucidate genetic differences 
between them and the molecular pathways that lead to tumor progression, and to identify prognostic biomarkers 
that could help us to tailor treatment in MIBC patients.
Results
Clinicopathological variable comparison between progressive and de novo MIBC. A total of 
212 MIBC patients (104 progressive and 108 de novo) were included in this study (Table 1). In a median follow-
up of 16 months, 99 (46.7%) patients progressed. Of them, 56 (26.4%) were from the progressive group [23 with 
LN(+)] and 43 (20.3%) from de novo group [19 with LN(+)]. The median time to progression was 8 months 
(8 and 9 months for progressive and de novo patients, respectively). All progressive MIBC patients who were 
treated with neoadjuvant chemotherapy (n = 6) progressed. On the other hand, 12 (41%) of de novo MIBC 
patients progressed after neoadjuvant chemotherapy treatment.
During the follow-up, 144 (67.9%) patients died; 87 (41%) of them due to cancer progression [51 (24%) from 
progressive (21 with LN (+)) and 36 (17%) from de novo (15 with LN(+)) group]. The median time of CSS was 
29 months (26 and 30 months for progressive and de novo patients, respectively). Progressive patients showed 
a significant difference in terms of survival compared with de novo patients (Fig. 1).
Discovery phase: gene expression patterns comparison between progressive and de novo 
MIBC. The analysis of 26 MIBC patients (Table 1) using Illumina microarray resulted in the identification of 
480 differently expressed transcripts between progressive and de novo MIBC groups (Supplementary Table S1); 
468 up-regulated and 12 down-regulated in progressive compared with de novo MIBC patients. Heat map based 
on the 50 most differently expressed genes shows a clear distinction between both groups (Fig.  2A). GSEA 
based on Hallmark, KEGG and Reactome databases identified that overexpressed genes were positively enriched 
in pathways such as epithelial-mesenchymal transition (EMT), muscle-contraction, regulation of NFKB in 
response to TNFA, and extracellular matrix organization (Fig. 2B).
Gene expression validation. A total of 94 genes were analyzed by qPCR in a cohort of 186 MIBC patients 
(Table 1). Twenty-four out of 94 genes were found to be differently expressed between progressive and de novo 
MIBC samples (Table 2). Of note, all genes were overexpressed in progressive compared with de novo MIBC 
patients. The USP42 gene has a different sense of differential expression in microarray and qPCR experiments, 
therefore this gene cannot be considered. Using the remaining 23 genes, a network using GeneMANIA was 
generated. We found that there is co-expression and physical interactions between the vast majority of these 23 
DEGs (Supplementary Fig. S1A). Moreover, several pathways were significantly enriched by this gene expression 
profile such as focal adhesion, PTK6 expression, muscle contraction and proteoglycans in cancer (Supplemen-
tary Fig. S1B).
Survival analysis. Since we found that progressive and de novo MIBC show different gene expression pat-
terns, survival analysis was performed independently in each of the groups. Additionally, only LN(−) patients 
were evaluated in this analysis, since lymph node status is unknown at the time of TURB. Furthermore, LN(+) 
patients had significantly worse outcomes than LN(−) patients (Supplementary Fig. S2), which could introduce 
a bias in the analysis. Thus, 132 patients were included in this analysis (55 progressive and 77 de novo).
Clinical and molecular variables were evaluated by Cox regression analysis (Tables 3, 4). Univariate and 
multivariate regression analysis for tumor progression showed that expression of RBPMS2 and DSC3 were found 
to be independent prognostic biomarkers in progressive and de novo MIBC groups, respectively. Furthermore, 
univariate and multivariate regression analysis for CSS showed that CALD1 and LCOR were found to be inde-
pendent prognostic biomarkers in progressive and de novo MIBC groups, respectively. 
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Thereafter, the median expression value of each prognostic biomarker was used as a cut-off point to classify 
patients into high-risk and low-risk groups for tumor progression and CSS. Figure 3 shows the Kaplan–Meier 
curves of the biomarkers in progressive and de novo MIBC patients generated using the selected cut-off point. 
As shown, expression values were able to discriminate between two groups of MIBC patients with a significant 
different probability of tumor progression and CSS.
Table 1.  Demographic and clinicopathological characteristics of enrolled patients. a Last NMIBC stage was not 
available in 14 progressive patients.
Overall Discovery phase Validation phase
De novo Progressive De novo Progressive De novo Progressive
MIBC MIBC MIBC MIBC MIBC MIBC
N (%) N (%) N (%) N (%) N (%) N (%)
Overall 108 104 12 14 96 90
Gender
Male 90 (83.3) 69 (66.3) 12 (100) 13 (92.9) 78 (81.2) 56 (62.2)
Female 18 (16.7) 35 (33.7) – 1 (7.1) 18 (18.8) 34 (37.8)
Median age (years) 69 72 66 74 72 71
Pathological stage
pT0–T1 28 (26) 11 (10.6) 8 (66.6) 1 (7.1) 20 (20.8) 10 (11.1)
pT2 50 (46.3) 46 (44.2) – 9 (64.3) 50 (52.1) 38 (42.2)
pT3 20 (18.5) 29 (27.9) 2 (16.7) 3 (21.5) 18 (18.8) 26 (28.9)
pT4 10 (9.2) 18 (17.3) 2 (16.7) 1 (7.1) 8 (8.3) 16 (17.8)
Carcinoma in situ (CIS) 36 (33.3) 20 (19.2) 7 (58.3) 3 (21.5) 29 (30.2) 17 (18.9)
Lymph nodes (LN)
LN(+) 20 (18.5) 30 (28.8) 3 (25) – 17 (17.7) 30 (33.3)
LN(−) 88 (81.5) 74 (71.2) 9 (75) 14 (100) 79 (82.3) 60 (66.7)
Neoadjuvant Chemotherapy 29 (26.8) 6 (5.6) 10 (83.3) – 19 (19.8) 6 (6.7)
Median TURBT Number – 3 – 3 – 2.5
Last NMIBC stagea –
T0 – 7 (6.7) – 2 (14.3) – 5 (5.6)
Ta – 23 (22.1) – 3 (21.5) – 20 (22.2)
T1 – 49 (47.1) – 8 (57.1) – 41 (45.6)
CIS – 11 (10.6) – 1 (7.1) – 10 (11.1)
Figure 1.  Kaplan–Meier curve for (A) tumor progression and (B) cancer specific survival comparing 
progressive and de novo MIBC groups.
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Figure 2.  Gene expression profiles in progressive and de novo MIBC samples. (A) Heat map displaying the 
50 most differently expressed genes between progressive and de novo MIBC samples. Red pixels correspond to 
an increased abundance of mRNA in the samples, whereas green pixels indicate decreased mRNA levels. Rows 
represent genes and columns represent experimental samples. (B) Gene set enrichment analysis (GSEA) shows 
positive correlation of overexpressed genes in pathways involved in tumor progression.
Table 2.  Significant DEGs between progressive and de novo MIBC of validation phase (RT-qPCR) and 
comparison with fold change in genes from the discovery phase (Microarray). The source from what the gene 
was taken (microarray/literature) is also shown. FDR False Discovery Rate.
Gene Source
Validation phase Discovery phase
FDR Fold change p-Value Fold change
ABCC9 Microarray 0.04 3.41 < 0.001 4.10
ARL5A Microarray 0.001 1.49 0.001 2.47
CALD1 Microarray < 0.001 3.34 < 0.001 3.90
FLNC Microarray < 0.001 4.48 0.001 4.83
GEM Microarray 0.004 3.13 0.003 3.06
HIF1A Microarray < 0.001 1.99 < 0.001 3.30
RGS2 Microarray 0.001 4.54 < 0.001 4.25
SMAD5 Microarray 0.001 1.84 < 0.001 2.82
USP42 Microarray 0.001 2.23 < 0.001 − 5.30
ITGA5 Microarray < 0.001 3.68 < 0.001 4.26
CD44 Literature < 0.001 2.98 0.071 − 1.48
PDCD1LG2 Literature 0.004 2.26 0.814 1.09
IDO1 Literature 0.02 2.31 0.579 − 1.16
PGM5 Literature < 0.001 5.40 0.308 1.57
DES Literature < 0.001 7.68 0.779 1.16
C7 Literature < 0.001 4.77 0.067 2.09
SFRP4 Literature  < 0.001 5.28 0.119 2.45
COMP Literature < 0.001 3.60 0.752 1.21
ZEB1 Literature  < 0.001 3.33 0.071 1.59
ZEB2 Literature < 0.001 2.83 0.210 1.32
TWIST1 Literature 0.003 8.22 0.886 1.04
MSN Literature 0.001 1.94 0.834 − 1.07
NR3C1 Literature 0.001 1.97 0.330 1.21
CTSE Literature 0.007 2.35 0.238 1.66
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Discussion
Several studies have reported that patients with MIBC with a previous history of a non-invasive tumor present a 
worse outcome compared with de novo MIBC patients after  RC6,7,9. However, these studies are only based on the 
clinicopathological characteristics of the tumor and no data regarding different molecular features of progressive 
and de novo MIBC are reported in the literature to date. Here, we have characterized gene expression profiles of 
progressive and de novo MIBC. Furthermore, we identified prognostic markers in each group of MIBC patients 
that may contribute to tailor treatment strategies.
Our series corroborates that progressive patients have a worse prognosis than de novo MIBC, as previously 
 reported6,7,10. Furthermore, all progressive MIBC patients who were treated with neoadjuvant chemotherapy 
progressed to metastasis, confirming that these patients have a worse response to this therapy than de novo 
MIBC  patients10. The more aggressive behavior of progressive MIBC could be explained by two hypotheses. First, 
intravesical and cytotoxic cancer therapies administered to NMIBC would induce selection of resistant clones 
which could play an important role in tumor progression. Second, TURBT could promote the intravesical and 
hematogenous spread of tumor  cells9. This is supported by the detection of circulating tumor cells in NMIBC 
patients after, but not before  TURBT13. On the contrary, this more aggressive pattern of progressive MIBC could 
be simply explained by late muscle invasive tumor diagnosis and delayed radical  cystectomy14. Therefore, NMIBC 
patients with high-risk of progression to muscle invasion may be considered for an early cystectomy. In fact, early 
cystectomy is already performed in some high-grade NMIBC selected patients according to urologic guidelines 
in several centers, including  ours12,15–17.
To the best of our knowledge, this is the first report demonstrating that progressive and de novo MIBC pre-
sent distinct molecular signatures. Moreover, we have found that genes overexpressed in progressive MIBC are 
involved in pathways such as EMT, muscle contraction, TNFA signaling and extracellular matrix organization. 
All these pathways promote tumor progression and  invasion18–21, corroborating that gene expression differences 
between progressive and de novo MIBC may account for the different clinical outcome of these patients. Valida-
tion of a subset of these DEGs in an independent and larger cohort further supported data from discovery phase. 
We found that validated genes are involved in pathways like focal adhesion, PTK6 expression, muscle contraction 
and proteoglycans in cancer. Focal adhesion is an essential step in cell migration and its dysregulation promotes 
cell invasion and  metastasis22; PTK6 is a protein that regulates normal cell growth, but in tumors it contributes 
Table 3.  Tumor progression in progressive and de novo MIBC patients. HR Hazard ratio, CI confidence 
interval. *Statistically significant values are in bold.
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
(A) Progressive MIBC
FLNC 2.73 (1.06–7.05) 0.038 – 0.503
FGFR1 2.93 (1.14–7.56) 0.026 – 0.150
RBPMS2 3.97 (1.23–12.75) 0.021 8.73 (1.72–44.23) 0.009*
Pathological stage 1.50 (1.07–2.09) 0.017 – 0.332
(B) De novo MIBC
ITGA5 2.61 (1.17–5.83) 0.019 – 0.110
DSC3 0.21 (0.08–0.55) 0.001 0.20 (0.05–0.75) 0.017*
MSI1 2.97 (1.08–8.15) 0.034 – 0.490
PGM5 2.51 (1.03–6.10) 0.042 – 0.056
SNAI1 2.56 (1.02–6.42) 0.046 – 0.727
Table 4.  Cancer-specific survival in progressive and de novo MIBC patients. HR Hazard ratio, CI confidence 
interval. *Statistically significant values are in bold..
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
(A) Progressive MIBC
CALD1 2.62 (0.99–6.93) 0.044 6.24 (1.37–28.40) 0.018*
Pathological stage 1.43 (0.98–2.09) 0.049 - 0.060
(B) De novo MIBC
CALD1 2.40 (1.01–5.73) 0.048 – 0.738
LCOR 3.16 (1.30–7.66) 0.011 6.75 (2.03–22.42) 0.002*
ITGA5 2.55 (1.09–5.99) 0.031 – 0.206
DSC3 0.23 (0.08–0.64) 0.005 – 0.371
MSI1 3.19 (1.04–9.78) 0.042 – 0.355
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to cell proliferation by sensitizing cells to mitogenic  signals23; cell contraction and motility is regulated by calde-
smon, a component of cytoskeleton in muscle  cells19, suggesting that up-regulation of CALD1 in progressive 
patients could promote cell motility and invasion. Eventually, proteoglycans are key macromolecules that con-
tribute to proliferation, angiogenesis and metastasis, promoting cancer  progress24. Therefore, these pathways 
play a crucial role in tumor migration and invasion, promoting  EMT18,25.
Finally, we have been able to identify prognostic biomarkers to predict the clinical outcome in each group 
of MIBC patients. We found that RBPMS2 and DSC3 are prognostic biomarkers for tumor progression in pro-
gressive and de novo MIBC, respectively. Over-expression of RBPMS2, a protein involved in the regulation of 
muscle cell differentiation and  proliferation26, and down-regulation of DSC3, a member of the cadherin family 
implicated in cell–cell adhesion, have been found in other solid tumors, according our results. DSC3 has also 
been previously described as a prognostic biomarker in various solid  tumors27–29.
On the other hand, we found CALD1 and LCOR as prognostic biomarkers for CSS in progressive and de novo 
MIBC, respectively. According to our results, over-expression of CALD1, a protein that regulates cell motility, 
and LCOR, a protein that modulates expression of the estrogen receptor, has been previously associated with 
poor prognosis in bladder and other solid  tumors30,31.
The relevance of the present work falls on the fact that it is the first report to describe molecular differ-
ences between progressive and de novo MIBC in a balanced and multicentric cohort. The methodology used to 
analyze these biomarkers is widely available, reasonably simple and inexpensive, and thus they could be easily 
implemented in clinical practice. Consequently, gene expression of MIBC could be easily detected from TURBT 
samples and those patients with a high-risk of progression to distant metastasis or cancer specific mortality could 
benefit from early adjuvant treatments.
Figure 3.  Kaplan–Meier curves for (A) tumor progression and (B) cancer specific survival of prognostic 
biomarkers in progressive and de novo MIBC groups.
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However, we have to acknowledge some limitations. Given the heterogeneity of bladder cancer, one limita-
tion of this study is that we have sampled only one segment of the tumor. Detection of gene expression in liquid 
biopsy samples could overcome this limitation. In addition, patients with LN(+) have been excluded from survival 
analysis due to the increased risk of progression of LN(+) patients, decreasing sample size. Therefore, the study 
has a limited size which can limits the statistical power of the study. A final validation of the results in a larger, 
independent series is necessary to define the real role of these biomarkers and for their clinical implementation.
Conclusions
Progressive and de novo MIBC patients show different gene expression profiles. Progressive patients show over-
expression of genes involved in tumor invasion and migration, resulting in a worse prognosis of these patients 
compared with the de novo MIBC group. Progressive and de novo MIBC groups present different prognostic 
biomarkers for tumor progression (RBPMS2 in progressive MIBC and DSC3 in de novo MIBC) and for CSS 
(CALD1 in progressive MIBC and LCOR in de novo MIBC). These biomarkers may contribute to predict high-
risk of progression to distant metastasis or cancer specific mortality and consequently, to tailor treatment and 
surveillance strategies in these patients.
Materials and methods
Patients and samples. Retrospective multicenter study including 212 patients (median age 72 (range 
37–100) years; 159 males, 53 females) with MIBC who underwent radical cystectomy with lymphadenectomy 
in two different centers (Hospital Clinic, Barcelona, Spain and Radboud University Medical Center, Nijmegen, 
The Netherlands) between 2000 and 2019. Two groups were formed: progressive MIBC, patients with primar-
ily NMIBC who showed progression to MIBC (N = 104) and de novo MIBC, patients with primarily MIBC 
(N = 108) (Table 1).
Samples were obtained either from transurethral resection of the bladder tumor (TURBT; N = 132) showing 
muscle-invasive disease or from cystectomy specimens (N = 80). At the moment of cystectomy, 50 MIBC patients 
had positive lymph nodes [LN(+)]. None of the patients had distant metastasis.
The work was approved by the Ethical Committee of the Clinical Investigation from Hospital Clinic, Barce-
lona, Spain. All the procedures were carried out in accordance with the relevant guidelines and regulations of 
CPMP/ICH/135/95. All tissue samples were obtained under an institutional review board-approved protocol 
and written informed consent was obtained from all participants.
Postoperative follow-up was in the first year 3-monthly and in the second and third year biannual. After 
3 years disease-free, patients were followed up yearly. In the follow-up abdominal and/or pelvic CT scans were 
performed. Tumors were considered progressive in case of local (relapse) or distant metastasis. Five patients 
were lost of follow-up.
Tissue specimens and RNA isolation. Formalin-fixed paraffin-embedded (FFPE) tissue sections of 
20 µm were obtained from IDIBAPS and Radboud University Medical Center tumor biobanks, without direct 
involvement of human participants. Total RNA was isolated from FFPE sections using the RecoverAll Total 
Nucleic Acid Isolation Kit (Ambion, Inc. Austin, TX, USA), according to the manufacturer’s instructions. RNA 
was quantified by spectrophotometric analysis at 260 nm (NanoDrop Technologies, Wilmington, DE, USA).
Discovery phase: whole‑genome gene expression microarray. A flowchart of the entire study is 
shown in Fig. 4. Global gene expression profiling of 26 randomly selected MIBC samples from Hospital Clinic 
(Table 1), Barcelona, Spain (14 progressive and 12 de novo), was performed by using Whole-Genome Gene 
Expression DASL HT Assay (Illumina, San Diego, CA, USA) according to manufacturer’s  instructions32. RNA 
quality control was performed by quantifying RPL13A by reverse transcription quantitative PCR (RT-qPCR) 
(Applied Biosystems, Foster City, CA, USA), following manufacturer’s instructions. All 26 samples had cycle 
quantification (Cq) values for RPL13A < 28, which are considered to be of acceptable RNA quality by microarray 
manufacturers (data not shown).
DASL gene expression data was processed employing quantile normalization using the Lumi bioconductor 
package. Those samples with a 75% of absent probes were discarded. Next, those probes with a coefficient of 
variation greater than 0.1 were excluded, which resulted in the selection of a total of 27,965 probes from the 
original set of 29,377. Detection of differentially expressed probes was performed using the SAMR  package33. 
Transcripts with a false discovery rate (FDR) < 0.05 were considered as differentially expressed.
R package version 2.0. was used for all calculations and to construct heatmaps (https ://CRAN.R-proje ct.org/
packa ge=samr). Gene set enrichment analysis (GSEA) was performed using GSEA2-2.2.0 software for testing 
specific gene set based on Hallmark, Kyoto Encyclopedia of Genes and Genomes (KEGG)34 and Reactome path-
way databases. Microarray files and clinical information were deposited into Gene Expression Omnibus (GEO) 
with the accession number: GSE149582 (Supplementary Table S2).
Validation of microarray expression. Differential expression of 94 genes, 35 genes chosen from micro-
array analysis (FDR < 0.05) and 59 genes from literature (Supplementary Table S3), was determined in an addi-
tional series of 186 patients from Hospital Clinic and Radboud UMC (Table 1) using Biomark 96.96 Dynamic 
Arrays (Fluidigm, South San Francisco, CA, USA).
Complementary DNA (cDNA) was synthesized from 100 ng of total RNA isolated from MIBC samples 
using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA), follow-
ing manufacturer’s instructions, except that the final volume of the reaction was 25 µl. Each cDNA sample was 
used for the multiplex pre-amplification using TaqMan PreAmp Master Mix Kit following the manufacturer’s 
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instructions (Applied Biosystems), except that the final volume of the reaction was 5 µl. A total of 94 target genes 
and 2 endogenous controls (GUSB and PPIA) were used in a cDNA pre-amplification reaction (Supplementary 
Table S3). After pre-amplification, quantitative PCR (qPCR) was used to control RNA quality. Samples with 
GUSB Cq values between 18 and 24 were considered of acceptable RNA quality and used for further analysis.
Pre-amplified cDNA and TaqMan Gene Expression Assays 20X (Applied Biosystems) were loaded into the 
BioMark 96.96 Dynamic Arrays (Fluidigm, South San Francisco, CA, USA) following the manufacturer’s instruc-
tions. The real-time qPCR experiments were performed on the Biomark HD system (Fluidigm Corporation).
Fluidigm Real-Time PCR Analysis Software was used to obtain Cq values. Relative expression levels of target 
genes within a sample were expressed as ΔCq (ΔCq = Cq endogenous control − Cq target gene). The mean Cq 
value of GUSB and PPIA was used as endogenous control. Genes with Cq > 34 were considered low expression and 
were not evaluated. Fold-change values were generated from the median expression of genes from the BioMark 
96.96 Dynamic Arrays of groups compared.
Assessment of differential gene expression was performed using the Student’s t test for independent samples. 
Samples with a p value < 0.05 were considered significant. The FDR method was used to correct p values for 
multiple comparisons.
Gene–gene functional interaction network for the differentially expressed genes (DEGs) was built by Gene-
MANIA Cytoscape 3.6.0  plugin35. Co-expression, physical and pathway gene–gene interactions were evaluated. 
ToppGene (https ://toppg ene.cchmc .org/)36 was used to identify significant pathways for DEGs.
Survival analysis. Univariate Cox regression analysis was performed on the clinical and molecular vari-
ables to examine its influence on tumor progression and CSS. Subsequently, multivariate Cox regression analysis 
was performed on significant variables. Statistical significance was established at a p-value of 0.05. Gene expres-
DISCOVERY PHASE
Whole genome gene 
expression microarray
14 progressive MIBC; 12 de novo MIBC
480 transcripts differently expressed
SAMR
94 genes selected: 35 
genes from microarray 





(90 progressive; 96 de novo)
9 and 14 genes differently 
expressed from microarray and 
literature, respectively
SURVIVAL ANALYSIS
(Cox multivariable regression analysis)
186 MIBC patients
(90 progressive; 96 de novo)








Figure 4.  Study outline. Tissue samples were obtained from a total of 104 progressive and 108 de novo MIBC 
patients. Samples were split into a discovery (26 samples) and validation phase (186 samples). Genes differently 
expressed between progressive and de novo MIBC patients were identified in the discovery phase by using 
gene expression microarray. None of the samples from the discovery phase were employed for the validation 
process. In this validation phase, the differential expression of 94 genes was evaluated. In survival analysis, 
RBPMS2 and DSC3 were identified as prognostic biomarkers for tumor progression in progressive and de novo 
MIBC, respectively; CALD1 and LCOR were identified as prognostic markers for CSS in progressive and de 
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sion was dichotomized using the median expression value of significant genes. Thereafter, Kaplan–Meier curves 
were generated.
All analyses were carried out with R-software and SPSS software package (IMB SPSS Statistics 23).
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